Everolimus
- Generic Name
- Everolimus
- Brand Names
- Afinitor, Votubia, Zortress
- Drug Type
- Small Molecule
- Chemical Formula
- C53H83NO14
- CAS Number
- 159351-69-6
- Unique Ingredient Identifier
- 9HW64Q8G6G
- Background
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
- Indication
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease.
Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.
Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.
Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
- Associated Conditions
- Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
- Associated Therapies
- -
Everolimus Post Orthotopic Liver Transplant
- First Posted Date
- 2013-12-02
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Tomoaki Kato
- Target Recruit Count
- 50
- Registration Number
- NCT01998789
- Locations
- 🇺🇸
Columbia University Medical Center-NYPH, New York, New York, United States
Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- Baylor College of Medicine
- Registration Number
- NCT01997255
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
Comparing Everolimus and Sirolimus in Renal Transplant Recipients
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 60
- Registration Number
- NCT01976390
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study
- Conditions
- Interventions
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 60
- Registration Number
- NCT01960829
- Locations
- 🇨🇳
LuSi, Beijing, Beijing, China
NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Jenny C. Chang, MD
- Target Recruit Count
- 24
- Registration Number
- NCT01931163
- Locations
- 🇺🇸
Houston Methodist Hospital Willowbrook, Houston, Texas, United States
🇺🇸The Methodist Hospital, Houston, Texas, United States
🇺🇸Houston Methodist Hospital Sugar Land, Sugar Land, Texas, United States
Rapalogues for Autism Phenotype in TSC: A Feasibility Study
- Conditions
- Interventions
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2021-03-29
- Target Recruit Count
- 3
- Registration Number
- NCT01929642
- Locations
- 🇺🇸
Kennedy Krieger Institute, Baltimore, Maryland, United States
Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2016-02-10
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 61
- Registration Number
- NCT01888042
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys
- Conditions
- Interventions
- First Posted Date
- 2013-06-17
- Last Posted Date
- 2019-04-26
- Lead Sponsor
- Matthew Cooper
- Target Recruit Count
- 25
- Registration Number
- NCT01878786
- Locations
- 🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States
Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
- Conditions
- Interventions
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT01864070
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT01854606
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center Onc. Dept., New York, New York, United States
🇺🇸Washington University School of Medicine Dept of Oncology., Saint Louis, Missouri, United States
🇺🇸Sarah Cannon Research Institute Dept of Onc, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.